Capricor Therapeutics CAPR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Capricor Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Capricor Therapeutics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Capricor Therapeutics's additional paid-in capital?
- Capricor Therapeutics (CAPR) reported additional paid-in capital of $617.72M in Q1 2026.
- How has Capricor Therapeutics's additional paid-in capital changed year-over-year?
- Capricor Therapeutics's additional paid-in capital increased by 76.5% year-over-year, from $350.01M to $617.72M.
- What is the long-term trend for Capricor Therapeutics's additional paid-in capital?
- Over 5 years (2020 to 2025), Capricor Therapeutics's additional paid-in capital has grown at a 39.3% compound annual growth rate (CAGR), from $116.22M to $610.33M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.